Intellipharmaceutics International Inc. (IPCIF)
| Market Cap | 4.64M |
| Revenue (ttm) | 1.40M |
| Net Income (ttm) | -3.39M |
| Shares Out | 33.09M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,113 |
| Open | 0.1313 |
| Previous Close | 0.1300 |
| Day's Range | 0.1313 - 0.1402 |
| 52-Week Range | 0.0588 - 0.4800 |
| Beta | 1.09 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Oct 14, 2021 |
About IPCIF
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for...
Financial Performance
In 2020, IPCIF's revenue was $1.40 million, a decrease of -59.73% compared to the previous year's $3.48 million. Losses were -$3.39 million, -58.06% less than in 2019.
Financial StatementsNews
Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Certification and Notice of Hearing for Settlement Appro...
TORONTO--(BUSINESS WIRE)--Kim Spencer McPhee Barristers, P.C. today announces a proposed securities class action settlement regarding Intellipharmaceutics International Inc. (“IPCI”). In 2019, a propose...
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...
Intellipharmaceutics Announces First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resear...
Intellipharmaceutics Announces Fiscal Year 2020 Results
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...